top of page
01.jpg

Advancing Therapeutic Development With Scientific Discipline

Sviorilex is a private, development-stage pharmaceutical

company advancing a portfolio of proprietary therapeutic compounds.

​

Built on approximately seven years of research and development, the company is now focused on advancing its lead program,

Alpha B2, through formal clinical development.

SVIORILEX
02.jpg

Alpha B2

Alpha B2 is the primary focus of Sviorilex’s development program.

​

Research and preclinical work have demonstrated activity across multiple disease areas, providing the scientific foundation for continued evaluation.

OUR LEAD PROGRAM
logoback.png
03.jpg

A Disciplined Approach to Development

Sviorilex advances its programs through a structured process in which scientific findings are evaluated, tested and progressively developed against established clinical and regulatory standards.

Our objective is simple: allow the evidence
to determine the therapeutic potential of each program.

04.jpg

Seven Years of Development.
The Next Stage Begins.

Years of foundational work have brought Sviorilex to its next phase: advancing Alpha B2 and its broader therapeutic portfolio toward formal clinical evaluation.

bottom of page